Dabrafenib, a B-raf inhibitor currently used in cancer therapies that was subsequently found to be a strong inhibitor of RIPK3 at moderate doses [40] has also been found to confer a neuroprotective benefit in cerebral ischemia. The gene discussed is RIPK3; the disease is Cerebral ischemia.